Teradyne Reports First Quarter 2020 Results

  • Revenue of $704 million in Q1’20, growth of 43% from Q1’19
  • Test revenue grew 50% from Q1’19
  • Industrial Automation revenue declined 9% from Q1’19 on global manufacturing weakness
  • Share repurchase program suspended as of April 1, 2020            
 Q1'20 Q1'19 Q4'19 
Revenue (mil)$704 $494  $655  
GAAP EPS$0.97 $0.62 $0.69  
Non-GAAP EPS$1.00 $0.54 $0.88  

NORTH READING, Mass., April 21, 2020 (GLOBE NEWSWIRE) -- Teradyne, Inc. (NASDAQ: TER) reported revenue of $704 million for the first quarter of 2020 of which $484 million was in Semiconductor Test, $116 million in System Test, $60 million in Industrial Automation (IA) and $43 million in Wireless Test. GAAP net income for the first quarter was $176.2 million or $0.97 per diluted share. On a non-GAAP basis, Teradyne’s net income in the first quarter was $172.5 million, or $1.00 per diluted share, which excluded acquired intangible asset amortization, restructuring and other charges, non-cash convertible debt interest, discrete tax adjustments and included the related tax impact on non-GAAP adjustments.

“First quarter sales and earnings were in line with our January guidance through the extraordinary efforts of our operations team, their supply line partners, and our customer support teams,” said CEO and President Mark Jagiela. “Production ramps of recent design wins in our System on a Chip and Memory test units continued as planned and the climate in our test businesses remains cautiously positive. However, our Industrial Automation results were below plan as we faced considerable headwinds from the COVID-19 related impacts on global manufacturing activity.

“While test demand remains strong entering the second quarter and our balance sheet has over $900 million in available cash, the impacts of the global pandemic on short term Test and Industrial Automation demand remain uncertain. As a result, we are prudently managing our cash flow and have suspended our share repurchase program until there is more clarity on the economic front. Our second quarter guidance ranges are broader than usual to reflect that demand and supply uncertainty.”

Guidance for the second quarter of 2020 is revenue of $690 million to $800 million, with GAAP net income of $0.76 to $1.05 per diluted share and non-GAAP net income of $0.86 to $1.16 per diluted share. Non-GAAP guidance excludes acquired intangible asset amortization, non-cash convertible debt interest and includes the related tax impact on non-GAAP adjustments.

A conference call to discuss the first quarter results, along with management's business outlook, will follow at 8:30 a.m. ET, Wednesday, April 22. Interested investors should access the webcast at investors.teradyne.com/events-presentations at least five minutes before the call begins. Presentation materials will be available starting at 8:30 a.m. ET. A replay will be available on Teradyne’s Investor Relations site at investors.teradyne.com.

Non-GAAP Results
In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Non-GAAP income from operations and non-GAAP net income exclude acquired intangible assets amortization, non-cash convertible debt interest, pension actuarial gains and losses, discrete income tax adjustments, fair value inventory step-up, and restructuring and other, and includes the related tax impact on non-GAAP adjustments. GAAP requires that these items be included in determining income from operations and net income. Non-GAAP income from operations, non-GAAP net income, non-GAAP income from operations as a percentage of revenue, non-GAAP net income as a percentage of revenue, and non-GAAP net income per share are non-GAAP performance measures presented to provide meaningful supplemental information regarding Teradyne’s baseline performance before gains, losses or other charges that may not be indicative of Teradyne’s current core business or future outlook. These non-GAAP performance measures are used to make operational decisions, to determine employee compensation, to forecast future operational results, and for comparison with Teradyne’s business plan, historical operating results and the operating results of Teradyne’s competitors. Non-GAAP gross margin excludes fair value inventory step-up. GAAP requires that this item be included in determining gross margin. Non-GAAP gross margin dollar amount and percentage are non-GAAP performance measures that management believes provide useful supplemental information for management and the investor. Management uses non-GAAP gross margin as a performance measure for Teradyne’s current core business and future outlook and for comparison with Teradyne’s business plan, historical gross margin results and the gross margin results of Teradyne’s competitors. Non-GAAP diluted shares include the impact of Teradyne’s call option on its shares. Management believes each of these non-GAAP performance measures provides useful supplemental information for investors, allowing greater transparency to the information used by management in its operational decision making and in the review of Teradyne’s financial and operational performance, as well as facilitating meaningful comparisons of Teradyne’s results in the current period compared with those in prior and future periods. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at www.teradyne.com by clicking on “Investor Relations” and then selecting “Financials” and the “GAAP to Non-GAAP Reconciliation” link. The non-GAAP performance measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

About Teradyne
Teradyne (NASDAQ:TER) brings high-quality innovations such as smart devices, life-saving medical equipment and data storage systems to market, faster. Its advanced test solutions for semiconductors, electronic systems, wireless devices and more ensure that products perform as they were designed. Its Industrial Automation offerings include collaborative and mobile robots that help manufacturers of all sizes improve productivity and lower costs. In 2019, Teradyne had revenue of $2.3 billion and today employs 5,500 people worldwide. For more information, visit teradyne.com. Teradyne® is a registered trademark of Teradyne, Inc. in the U.S. and other countries.

Safe Harbor Statement
This release contains forward-looking statements regarding Teradyne’s future business prospects, the impact of the COVID-19 outbreak, results of operations, market conditions, earnings per share, the payment of a quarterly dividend, the repurchase of Teradyne common stock pursuant to a share repurchase program, and the impact of the U.S. export and tariff laws. Such statements are based on the current assumptions and expectations of Teradyne’s management and are neither promises nor guarantees of future performance, events, earnings per share, use of cash, payment of dividends, repurchases of common stock, payment of the senior convertible notes, the impact of the COVID-19 outbreak, or the impact of the U.S. export and tariff laws. There can be no assurance that management’s estimates of Teradyne’s future results or other forward-looking statements will be achieved. Additionally, the current dividend program may be modified, suspended or discontinued at any time.

On May 16, 2019, Huawei and 68 of its affiliates, including HiSilicon, were added to the U.S. Department of Commerce Entity List under U.S. Export Administration Regulations (the “EAR”). This action by the U.S. Department of Commerce imposed new export licensing requirements on exports, re-exports, and in-country transfers of all U.S. - regulated products, software and technology to the designated Huawei entities.  While most of Teradyne’s products are not subject to the EAR and therefore not affected by the Entity List restrictions, some of its products are currently manufactured in the U.S. and thus subject to the Entity List restrictions. Compliance with the current Entity List restrictions has not significantly impacted Teradyne’s sales. There have been recent news reports that the U.S. Department of Commerce plans to modify the U.S. EAR to expand the scope of the regulations to include additional products that would become subject to the Entity List restrictions relating to Huawei and the designated Huawei entities including HiSilicon. These modified regulations, if implemented as currently reported, may impact Teradyne’s sales to third party contract manufacturers used by Huawei and HiSilicon to manufacture and test semiconductor and other electronic devices. Because the business environment for Huawei is both fluid and uncertain, there are also risks that Huawei, HiSilicon and their third party contract manufacturers may have less demand for Teradyne’s products and/or may purchase products from Teradyne’s competitors who are not impacted by the U.S. regulations. Until these or any new regulations become public and effective, Teradyne will not know the extent of the impact on its business with Huawei, HiSilicon and their third party contract manufacturers. However, it is possible that these modified regulations and any other additional regulations that may be implemented by the U.S. Department of Commerce or other government agency would have a material impact on Teradyne’s business and financial results.

The global outbreak of the recent novel strain of the coronavirus (COVID-19) has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter in place orders, and shutdowns.  These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers.  Teradyne management believes COVID-19 has adversely impacted its results of operations, including increased costs, but cannot accurately estimate the amount of the impact for Teradyne’s first quarter 2020 financial results and to its future financial results. There is considerable uncertainty regarding the impact on Teradyne’s business from the measures in place and potential future measures, and restrictions on Teradyne’s access to its manufacturing facilities or on its support operations or workforce, or similar limitations for its contractor manufacturers and suppliers, and restrictions or disruptions of transportation, such as reduced availability of transportation and increased border controls or closures, could limit Teradyne’s capacity to meet customer demand and have a material adverse effect on its financial condition and results of operations. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty could result in a significant decrease in demand for Teradyne’s products for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of physical participation in meetings, events and conferences), and the company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be harmed. Due to the uncertainty regarding the length, severity and potential business impact of the COVID-19 pandemic, Teradyne has suspended its stock repurchase program. In January 2020, Teradyne announced its intention to repurchase $250 million in shares in 2020. At this time, Teradyne does not know whether or when it will continue its 2020 repurchase plan or authorize future stock repurchase programs. The degree to which COVID-19 impacts Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.

Important factors that could cause actual results, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the impact of the COVID-19 outbreak and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the consummation and success of any mergers or acquisitions; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the company’s best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei and HiSilicon; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the “Risk Factors” section of Teradyne’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019. The forward-looking statements provided by Teradyne in this press release represent management’s views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management’s views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne’s views as of any date subsequent to the date of this release.

 (In thousands, except per share amounts)
     Quarter Ended
     March 29,
 December 31,
 March 31,
Net revenues $704,355  $654,650  $494,099 
 Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1)  298,805   271,412   206,464 
Gross profit  405,550   383,238   287,635 
Operating expenses:      
 Selling and administrative  111,388   117,092   102,013 
 Engineering and development  85,159   86,794   76,791 
 Acquired intangible assets amortization  9,891   9,784   10,634 
 Restructuring and other (2)  (7,606)  (2,088)  5,112 
 Operating expenses  198,832   211,582   194,550 
Income from operations  206,718   171,656   93,085 
 Interest and other expense (3)  9,649   22,770   (894)
Income before income taxes  197,069   148,886   93,979 
 Income tax provision (benefit)  20,878   23,811   (15,159)
Net income $176,191  $125,075  $109,138 
Net income per common share:      
Basic   $1.06  $0.75  $0.63 
Diluted   $0.97  $0.69  $0.62 
Weighted average common shares - basic  166,589   167,286   173,532 
Weighted average common shares - diluted (4)  180,736   181,780   176,972 
Cash dividend declared per common share $0.10  $0.09  $0.09 
(1Cost of revenues includes: Quarter Ended
     March 29,
 December 31,
 March 31,
 Provision for excess and obsolete inventory $4,057  $6,396  $2,397 
 Sale of previously written down inventory  (1,077)  (1,222)  (778)
 Inventory step-up  118   64   - 
     $3,098  $5,238  $1,619 
(2Restructuring and other consists of: Quarter Ended
     March 29,
 December 31,
 March 31,
 Contingent consideration fair value adjustment $(10,020) $(2,796) $2,970 
 Acquisition related expenses and compensation  1,358   248   1,343 
 Employee severance  728   460   799 
 Other  328   -   - 
     $(7,606) $(2,088) $5,112 
(3Interest and other includes: Quarter Ended
     March 29,
 December 31,
 March 31,
 RealWear investment impairment $-  $15,000  $- 
 Non-cash convertible debt interest  3,540   3,496   3,368 
 Pension actuarial loss  -   7,727   - 
     $3,540  $26,223  $3,368 
(4Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended March 29, 2020, December 31, 2019, and March 31, 2019, 7.3 million, 7.3 million and 2.2 million shares, respectively, have been included in diluted shares. For the three months ended March 29, 2020, and December 31, 2019, diluted shares also included 5.5 million and 5.4 million shares, respectively, from the convertible note hedge transaction.
     March 29,
 December 31,
 Cash and cash equivalents $593,494  $773,924   
 Marketable securities  211,001   137,303   
 Accounts receivable, net  487,365   362,368   
 Inventories, net  182,978   196,691   
 Prepayments and other current assets  227,740   188,598   
 Total current assets  1,702,578   1,658,884   
 Property, plant and equipment, net  332,241   320,216   
 Operating lease right-of-use assets, net  58,808   57,539   
 Marketable securities  100,513   104,490   
 Deferred tax assets  74,493   75,185   
 Retirement plans assets  18,229   18,457   
 Other assets  9,272   10,332   
 Acquired intangible assets, net  114,321   125,480   
 Goodwill  409,933   416,431   
 Total assets   $2,820,388  $2,787,014   
 Accounts payable $129,633  $126,617   
 Accrued employees' compensation and withholdings  119,226   163,883   
 Deferred revenue and customer advances  98,815   104,876   
 Other accrued liabilities  87,274   70,871   
 Operating lease liabilities  19,591   19,476   
 Contingent consideration  662   9,106   
 Income taxes payable  58,760   44,200   
 Total current liabilities  513,961   539,029   
 Retirement plans liabilities  125,970   134,471   
 Long-term deferred revenue and customer advances  50,791   45,974   
 Deferred tax liabilities  11,628   14,070   
 Long-term other accrued liabilities  19,941   19,535   
 Long-term contingent consideration  19,810   30,599   
 Long-term operating lease liabilities  46,328   45,849   
 Long-term income taxes payable  82,820   82,642   
 Debt   398,466   394,687   
 Total liabilities    1,269,715   1,306,856   
Shareholders' equity  1,550,673   1,480,158   
 Total liabilities and shareholders' equity $2,820,388  $2,787,014   
     Quarter Ended  
     March 29,
 March 31,
Cash flows from operating activities:      
 Net income $176,191  $109,138   
 Adjustments to reconcile net income to net cash provided by operating activities:      
 Depreciation  18,489   16,651   
 Amortization  13,391   12,942   
 Stock-based compensation  10,460   9,474   
 Provision for excess and obsolete inventory  4,057   2,397   
 Losses (gains) on investments  4,657   (2,828)  
 Deferred taxes  (1,825)  1,206   
 Contingent consideration fair value adjustment  (10,020)  2,970   
 Other  503   219   
 Changes in operating assets and liabilities, net of businesses acquired:     
 Accounts receivable  (126,779)  (41,706)  
 Inventories  15,818   (2,917)  
 Prepayments and other assets  (39,620)  (18,648)  
 Accounts payable and other liabilities  (35,323)  (53,323)  
 Deferred revenue and customer advances  (913)  6,455   
 Retirement plans contributions  (1,262)  (1,210)  
 Income taxes  15,278   (22,804)  
Net cash provided by operating activities  43,102   18,016   
Cash flows from investing activities:      
 Purchases of property, plant and equipment  (36,700)  (25,711)  
 Purchases of marketable securities  (187,119)  (375,184)  
 Proceeds from maturities of marketable securities  98,457   141,201   
 Proceeds from sales of marketable securities  15,005   5,440   
 Acquisition of businesses, net of cash acquired  149   (6,970)  
 Proceeds from life insurance  -   273   
Net cash used for investing activities  (110,208)  (260,951)  
Cash flows from financing activities:      
 Issuance of common stock under stock purchase and stock option plans   12,752   14,268   
 Repurchase of common stock  (79,039)  (156,468)  
 Dividend payments  (16,686)  (15,627)  
 Payments related to net settlement of employee stock compensation awards   (22,070)  (14,318)  
 Payments of contingent consideration  (8,852)  (27,615)  
Net cash used for financing activities  (113,895)  (199,760)  
Effects of exchange rate changes on cash and cash equivalents  571   (329)  
Decrease in cash and cash equivalents  (180,430)  (443,024)  
Cash and cash equivalents at beginning of period  773,924   926,752   
Cash and cash equivalents at end of period $593,494  $483,728   


GAAP to Non-GAAP Earnings Reconciliation       
(In millions, except per share amounts)   
            Quarter Ended            
    March 29, 2020 % of Net Revenues     December 31, 2019 % of Net Revenues     March 31, 2019 % of Net Revenues    
Net revenues $704.4        $654.7        $494.1       
Gross profit GAAP and non-GAAP$405.6   57.6%     $383.2  58.5%     $287.6  58.2%    
 Inventory step-up 0.1   0.0%      0.1  0.0%      -  -     
Gross profit non-GAAP$405.7   57.6%     $383.3  58.5%     $287.6  58.2%    
Income from operations - GAAP$206.7   29.3%     $171.7  26.2%     $93.1  18.8%    
 Acquired intangible assets amortization 9.9   1.4%      9.8  1.5%      10.6  2.1%    
 Restructuring and other (1) (7.6)  -1.1%      (2.1) -0.3%      5.1  1.0%    
 Inventory step-up 0.1   0.0%      0.1  0.0%      -  -     
Income from operations - non-GAAP$209.1   29.7%     $179.5  27.4%     $108.8  22.0%    
        Net Income per Common Share     Net Income per Common Share     Net Income per Common Share
    March 29, 2020 % of Net Revenues Basic  Diluted December 31, 2019 % of Net Revenues Basic  Diluted March 31, 2019 % of Net Revenues Basic  Diluted
Net income - GAAP$176.2   25.0% $1.06  $0.97  $125.1  19.1% $0.75  $0.69  $109.1  22.1% $0.63  $0.62 
 Acquired intangible assets amortization 9.9   1.4%  0.06   0.05   9.8  1.5%  0.06   0.05   10.6  2.1%  0.06   0.06 
 Interest and other (2) 3.5   0.5%  0.02   0.02   18.5  2.8%  0.11   0.10   3.4  0.7%  0.02   0.02 
 Restructuring and other (1) (7.6)  -1.1%  (0.05)  (0.04)  (2.1) -0.3%  (0.01)  (0.01)  5.1  1.0%  0.03   0.03 
 Pension mark-to-market adjustment (2) -   -   -   -   7.7  1.2%  0.05   0.04   -  -   -   - 
 Inventory step-up 0.1   0.0%  0.00   0.00   0.1  0.0%  0.00   0.00   -  -   -   - 
 Exclude discrete tax adjustments (3) (7.7)  -1.1%  (0.05)  (0.04)  1.4  0.2%  0.01   0.01   (30.1) -6.1%  (0.17)  (0.17)
 Non-GAAP tax adjustments (1.9)  -0.3%  (0.01)  (0.01)  (7.8) -1.2%  (0.05)  (0.04)  (3.5) -0.7%  (0.02)  (0.02)
 Convertible share adjustment (4) -   -   -   0.04   -  -   -   0.03   -  -   -   0.01 
Net income - non-GAAP (4)$172.5   24.5% $1.04  $1.00  $152.7  23.3% $0.91  $0.88  $94.6  19.1% $0.55  $0.54 
GAAP and non-GAAP weighted average common shares - basic 166.6         167.3         173.5       
GAAP weighted average common shares - diluted 180.7         181.8         177.0       
 Exclude dilutive shares related to convertible note transaction   (7.3)        (7.3)        (2.2)      
Non-GAAP weighted average common shares - diluted 173.4         174.5         174.8       
(1Restructuring and other consists of:                       
    Quarter Ended      
    March 29, 2020       December 31, 2019       March 31, 2019      
 Contingent consideration fair value adjustment $(10.0)       $(2.8)       $3.0       
 Acquisition related expenses and compensation  1.4         0.2         1.3       
 Employee severance  0.7         0.5         0.8       
 Other   0.3         -         -       
    $(7.6)       $(2.1)       $5.1       
(2For the quarters ended March 29, 2020, December 31, 2019, and March 31, 2019, adjustment to exclude non-cash convertible debt interest expense. For the quarter ended December 31, 2019, adjustment to exclude actuarial loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting and adjustment to exclude RealWear $15.0 million investment impairment.     
(3For the quarters ended March 29, 2020, December 31, 2019, and March 31, 2019, adjustment to exclude discrete income tax items. For the quarter ended March 31, 2019, income tax (benefit) provision includes a $26 million tax benefit from the release of uncertain tax position reserves due to the IRS completion of its audit of Teradyne's 2015 Federal tax return.     
(4For the quarters ended March 29, 2020 and December 31, 2019, the non-GAAP diluted EPS calculation adds back $1.3 million of convertible debt interest expense to non-GAAP net income and non-GAAP weighted average diluted common shares include 5.5 million and 5.4 million shares, respectively, related to the convertible debt hedge transaction.     
GAAP to Non-GAAP Reconciliation of Second Quarter 2020 guidance:   
GAAP and non-GAAP second quarter revenue guidance:  $690 millionto$800 million                  
GAAP net income per diluted share  $0.76  $1.05                   
 Exclude acquired intangible assets amortization   0.06   0.06                   
 Exclude non-cash convertible debt interest   0.02   0.02                   
 Tax effect of non-GAAP adjustments   (0.02)  (0.02)                  
 Convertible share adjustment   0.04   0.05                   
Non-GAAP net income per diluted share  $0.86  $1.16                   
For press releases and other information of interest to investors, please visit Teradyne's homepage at: teradyne.com    
 Contact: Teradyne, Inc.                       
   Andy Blanchard 978-370-2425                 
   Vice President of Corporate Relations                 




Source: Teradyne, Inc.